S&P 500   4,564.10 (+0.30%)
DOW   35,500.72 (+0.47%)
QQQ   390.32 (+0.30%)
AAPL   190.80 (+0.53%)
MSFT   382.30 (+0.97%)
META   336.06 (+0.41%)
GOOGL   136.57 (+0.12%)
AMZN   147.24 (-0.33%)
TSLA   242.02 (+2.52%)
NVDA   480.32 (-0.44%)
NIO   7.24 (+0.70%)
BABA   75.98 (-2.00%)
AMD   122.19 (-0.38%)
T   16.17 (-0.25%)
F   10.39 (+0.48%)
MU   75.50 (-2.59%)
CGC   0.53 (-2.69%)
GE   119.62 (-0.29%)
DIS   94.08 (-1.15%)
AMC   6.69 (-1.62%)
PFE   29.99 (-0.50%)
PYPL   57.37 (+1.74%)
XOM   104.77 (+0.78%)
S&P 500   4,564.10 (+0.30%)
DOW   35,500.72 (+0.47%)
QQQ   390.32 (+0.30%)
AAPL   190.80 (+0.53%)
MSFT   382.30 (+0.97%)
META   336.06 (+0.41%)
GOOGL   136.57 (+0.12%)
AMZN   147.24 (-0.33%)
TSLA   242.02 (+2.52%)
NVDA   480.32 (-0.44%)
NIO   7.24 (+0.70%)
BABA   75.98 (-2.00%)
AMD   122.19 (-0.38%)
T   16.17 (-0.25%)
F   10.39 (+0.48%)
MU   75.50 (-2.59%)
CGC   0.53 (-2.69%)
GE   119.62 (-0.29%)
DIS   94.08 (-1.15%)
AMC   6.69 (-1.62%)
PFE   29.99 (-0.50%)
PYPL   57.37 (+1.74%)
XOM   104.77 (+0.78%)
S&P 500   4,564.10 (+0.30%)
DOW   35,500.72 (+0.47%)
QQQ   390.32 (+0.30%)
AAPL   190.80 (+0.53%)
MSFT   382.30 (+0.97%)
META   336.06 (+0.41%)
GOOGL   136.57 (+0.12%)
AMZN   147.24 (-0.33%)
TSLA   242.02 (+2.52%)
NVDA   480.32 (-0.44%)
NIO   7.24 (+0.70%)
BABA   75.98 (-2.00%)
AMD   122.19 (-0.38%)
T   16.17 (-0.25%)
F   10.39 (+0.48%)
MU   75.50 (-2.59%)
CGC   0.53 (-2.69%)
GE   119.62 (-0.29%)
DIS   94.08 (-1.15%)
AMC   6.69 (-1.62%)
PFE   29.99 (-0.50%)
PYPL   57.37 (+1.74%)
XOM   104.77 (+0.78%)
S&P 500   4,564.10 (+0.30%)
DOW   35,500.72 (+0.47%)
QQQ   390.32 (+0.30%)
AAPL   190.80 (+0.53%)
MSFT   382.30 (+0.97%)
META   336.06 (+0.41%)
GOOGL   136.57 (+0.12%)
AMZN   147.24 (-0.33%)
TSLA   242.02 (+2.52%)
NVDA   480.32 (-0.44%)
NIO   7.24 (+0.70%)
BABA   75.98 (-2.00%)
AMD   122.19 (-0.38%)
T   16.17 (-0.25%)
F   10.39 (+0.48%)
MU   75.50 (-2.59%)
CGC   0.53 (-2.69%)
GE   119.62 (-0.29%)
DIS   94.08 (-1.15%)
AMC   6.69 (-1.62%)
PFE   29.99 (-0.50%)
PYPL   57.37 (+1.74%)
XOM   104.77 (+0.78%)

Mind Medicine (MindMed) Stock Price, News & Analysis (NASDAQ:MNMD)

$3.03
0.00 (0.00%)
(As of 11:51 AM ET)
Compare
Today's Range
$2.91
$3.05
50-Day Range
$2.43
$4.03
52-Week Range
$2.12
$5.01
Volume
123,846 shs
Average Volume
481,508 shs
Market Capitalization
$120.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.43

Mind Medicine (MindMed) MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
756.2% Upside
$25.43 Price Target
Short Interest
Healthy
11.13% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$93,652 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.14) to ($1.76) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

Medical Sector

556th out of 935 stocks

Medicinals & Botanicals Industry

5th out of 12 stocks


MNMD stock logo

About Mind Medicine (MindMed) Stock (NASDAQ:MNMD)

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company working to develop therapies and treatments based on psychoactive substances. The company develops novel products including psychoactive substances and digital medicine to treat brain health disorders related to psychiatry, addiction, pain, and neurology. Digital medicine is the use of technology to measure and intervene in the service of human health and is a budding industry of its own. The company has 10 compounds in pre-clinical or clinical trials and 4 are on track to advance to Phase 1. The company is headquartered in Vancouver, Canada.

Mind Medicine’s pipeline of drug candidates is based on emerging science that more than suggests psychoactive substances can be used to relieve stress and anxiety disorders in the brain. Among the many potential uses for these drugs is the treatment of anxiety and stress related to PTSD and secondary stress disorders related to the treatment of people suffering from stress and anxiety-related disorders. Psychoactive compounds have also been shown to be effective in treating autism, pain, and social disorders.

The company’s treatments are focused on neuroplasticity or the fact our brain function is tied to its structure and the structure of our brains can change over time. When used in the proper context, Mind Medicine’s treatments aid the restructuring of brain activity and how it organizes information by catalyzing plasticity. In some cases, patients under treatment learn to make positive associations in relation to stress-inducing stimuli while under the influence of the treatments.

In addition to plasticity, psychoactive drugs like LSD, psilocybin, and DMT have been shown to have experiential effects such as lowering mental barriers and reducing defensive and often reflexive mechanisms that can be an impediment to healing.

Among the benefits of using psychoactive compounds versus traditional therapeutics are the speed of efficacy and greatly reduced side effects. Psychoactive drugs can produce positive effects in patients with the first use while it may take weeks for the current treatments to take effect and they come with many side effects. In some cases, side effects of mainstream treatments include an increase in suicidal behavior.

The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain. MM-120 is LSD D-tartrate. MM-110 is a nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal.

Mind Medicine also develops MM-402 which is for the treatment of core symptoms of autism spectrum disorder. This treatment is based on MDMA and improves sociability in autistic patients without stimulants and is shown to have superior safety and tolerability.

 

MNMD Stock Price History

MNMD Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
MNMD Mind Medicine (MindMed) Inc.
7 Best Psychedelic Stocks to Watch
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
The Latest Analyst Ratings for Mind Medicine
See More Headlines
Receive MNMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mind Medicine (MindMed) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2023
Today
11/28/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/14/2024

Industry, Sector and Symbol

Industry
Medicinals & botanicals
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MNMD
Fax
N/A
Employees
48
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$25.43
High Stock Price Target
$75.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+739.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-56,800,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.97 per share

Miscellaneous

Free Float
38,879,000
Market Cap
$120.35 million
Optionable
Not Optionable
Beta
2.24
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Robert Barrow (Age 34)
    CEO & Director
    Comp: $956.1k
  • Mr. Schond L. Greenway M.B.A. (Age 51)
    Chief Financial Officer
    Comp: $343.28k
  • Dr. Daniel Rollings Karlin M.A. (Age 42)
    M.D., Chief Medical Officer
    Comp: $663.63k
  • Dr. Miriam Halperin Wernli Ph.D. (Age 70)
    Executive President
    Comp: $552.46k
  • Dr. Scott M. Freeman M.D. (Age 66)
    Co-Founder & Clinical Advisor
    Comp: $314.75k
  • Mr. Leonard Latchman
    Co-founder
  • Ms. Carrie F. Liao CPA
    CGMA, VP & Chief Accounting Officer
  • Mr. Maxim Jacobs C.F.A.
    Vice President of Investor Relations & Corporate Communications
  • Mr. Mark R. Sullivan J.D. (Age 52)
    Chief Legal Officer & Corporate Secretary
  • Dr. Francois P. Lilienthal M.B.A.
    M.D., Chief Commercial Officer














MNMD Stock Analysis - Frequently Asked Questions

Should I buy or sell Mind Medicine (MindMed) stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mind Medicine (MindMed) in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MNMD shares.
View MNMD analyst ratings
or view top-rated stocks.

What is Mind Medicine (MindMed)'s stock price target for 2024?

7 analysts have issued 12-month price targets for Mind Medicine (MindMed)'s shares. Their MNMD share price targets range from $7.00 to $75.00. On average, they expect the company's share price to reach $25.43 in the next year. This suggests a possible upside of 756.2% from the stock's current price.
View analysts price targets for MNMD
or view top-rated stocks among Wall Street analysts.

How have MNMD shares performed in 2023?

Mind Medicine (MindMed)'s stock was trading at $2.20 on January 1st, 2023. Since then, MNMD shares have increased by 35.0% and is now trading at $2.97.
View the best growth stocks for 2023 here
.

When is Mind Medicine (MindMed)'s next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024.
View our MNMD earnings forecast
.

How were Mind Medicine (MindMed)'s earnings last quarter?

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) posted its quarterly earnings data on Thursday, November, 2nd. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.12.

What ETF holds Mind Medicine (MindMed)'s stock ?

AdvisorShares Psychedelics ETF holds 123,228 shares of MNMD stock, representing 7.16% of its portfolio.

When did Mind Medicine (MindMed)'s stock split?

Mind Medicine (MindMed)'s stock reverse split on the morning of Monday, August 29th 2022. The 1-15 reverse split was announced on Monday, August 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Who are Mind Medicine (MindMed)'s major shareholders?

Mind Medicine (MindMed)'s stock is owned by a number of retail and institutional investors. Top institutional shareholders include Busey Trust CO (0.52%), Charles Schwab Investment Management Inc. (0.47%), Group One Trading L.P. (0.00%), AdvisorShares Investments LLC (0.30%), Citigroup Inc. (0.22%) and Jump Financial LLC (0.09%). Insiders that own company stock include Dan Karlin, Robert Barrow and Schond L Greenway.
View institutional ownership trends
.

How do I buy shares of Mind Medicine (MindMed)?

Shares of MNMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:MNMD) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -